Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Fried

Showing results (91-100 of 166) with videos related to

Pageof 17
Sort By:
Hepatology (Baltimore, Md.)|September 26, 2002
Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirinMichael W Fried, Joy Peter, Keith Hoots, et al.
Hepatology (Baltimore, Md.)|January 29, 2008
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis BMichael W Fried, Teerha Piratvisuth, George K K Lau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United StatesMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2020
Reply to Roussel et alMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.
Epidemiology (Cambridge, Mass.)|January 31, 2023
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2008
Hepatitis C virus: a critical appraisal of approaches to therapyDavid R Nelson, Gary L Davis, Ira Jacobson, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Journal of Hepatology|September 10, 2002
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.
The American Journal of Gastroenterology|July 6, 2004
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 5, 2023
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world CohortArun J Sanyal, Breda Munoz, Kenneth Cusi, et al.
Pageof 17

Showing results (91-100 of 166) with videos related to

Sort By:
Pageof 17
Hepatology (Baltimore, Md.)|September 26, 2002
Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirinMichael W Fried, Joy Peter, Keith Hoots, et al.
Hepatology (Baltimore, Md.)|January 29, 2008
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis BMichael W Fried, Teerha Piratvisuth, George K K Lau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2020
Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United StatesMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2020
Reply to Roussel et alMichael W Fried, Julie M Crawford, Andrea R Mospan, et al.
Epidemiology (Cambridge, Mass.)|January 31, 2023
Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial EmulationAlexander Breskin, Catherine Wiener, Adaora A Adimora, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 31, 2008
Hepatitis C virus: a critical appraisal of approaches to therapyDavid R Nelson, Gary L Davis, Ira Jacobson, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Journal of Hepatology|September 10, 2002
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee, E Jenny Heathcote, K Rajender Reddy, et al.
The American Journal of Gastroenterology|July 6, 2004
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros, Robert Carithers, Paul Desmond, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 5, 2023
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world CohortArun J Sanyal, Breda Munoz, Kenneth Cusi, et al.
Pageof 17